GlassScriptPhysician profile
Zhuoyan Li
NPI 1619387867
$42,259.68
in general payments reported to CMS, 2019-2025
41 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $7,988 · 2024: $16K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,461 · Travel and Lodging: $1,246 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,787.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,230.00 |
| Food and Beverage | $5,460.99 |
| Travel and Lodging | $1,245.79 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29,980.49 | 2022-2025 | Calquence, Lumoxiti, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $6,868.03 | 2022-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $1,680.63 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Gilead Sciences, INC. | $471.61 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $335.64 | 2022-2025 | Enhertu, Datroway |
| Incyte Corporation | $317.72 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Biotech, INC. | $288.72 | 2024-2025 | Rybrevant, Tecvayli, Carvykti |
| Celgene Corporation | $284.55 | 2024-2025 | Reblozyl |
| Genentech USA, INC. | $269.03 | 2022-2025 | Tecentriq, Phesgo, Polivy |
| Abbvie INC. | $214.82 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $150.89 | 2022-2025 | Keytruda, Reblozyl, Lynparza |
| Novartis Pharmaceuticals Corporation | $118.08 | 2023-2025 | |
| Lilly USA, LLC | $113.73 | 2023-2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $110.83 | 2023-2025 | Libtayo |
| Exelixis INC. | $105.69 | 2024-2025 | Cabometyx |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $86.60 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $80.06 | 2023-2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $63.40 | 2025 | |
| Alexion Pharmaceuticals, INC. | $61.05 | 2023-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $60.97 | 2024-2025 | Jemperli, Zejula |
| Genzyme Corporation | $58.99 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $41.80 | 2025 | Vivimusta, Danziten |
| Caris Mpi, INC. | $41.51 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $41.04 | 2023-2025 | Loqtorzi |
| Eisai INC. | $40.27 | 2025 | |
| Puma Biotechnology, INC. | $32.41 | 2025 | |
| Astellas Pharma US INC | $29.16 | 2025 | Vyloy |
| Genmab U.S., INC. | $28.17 | 2024 | Epkinly |
| Array Biopharma INC | $27.20 | 2025 | Mektovi, Braftovi |
| Tolmar, INC. | $27.15 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $27.15 | 2025 | Rubraca |
| Pharmaessentia USA Corporation | $26.52 | 2023 | Besremi |
| Beone Medicines USA, INC. | $25.87 | 2025 | Tevimbra |
| Kite Pharma, INC. | $25.34 | 2025 | Yescarta |
| Sandoz INC. | $25.13 | 2025 | Jubbonti |
| Morphosys, US INC. | $24.79 | 2023 | Monjuvi |
| Pfizer INC. | $23.36 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.29 | 2025 | Onivyde |
| Servier Pharmaceuticals LLC | $15.84 | 2025 | |
| Adc Therapeutics America, INC. | $15.15 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhuoyan Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.